The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy: The Swiss HIV Cohort Study
Open accessAbstract
CONTEXT: Acquired immunodeficiency syndrome-related opportunistic illnesses (Ols) continue to occur after initiation of potent antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection. Risk factors for clinical progression to Ols during potent therapy are not well defined. OBJECTIVE: To examine the incidence of and risk factors for Ols among patients treated with potent antiretroviral therapy in a population-based study. DESIGN: The Swiss HIV Cohort Study, a prospective cohort study of adult HIV-infected persons. SETTING: Seven study centers throughout Switzerland. PATIENTS: A total of 2410 cohort study participants with a potential follow-up of at least 15 months after starting potent therapy between September 1995 and December 1997. MAIN OUTCOME MEASURES: Disease-specific incidence of Ols during the 6 months preceding potent antiretroviral therapy and at 3 intervals after initiating therapy; risk factors for development of Ols during therapy. RESULTS: Of the 2410 participants, 143 developed 186 Ols after initiation of potent antiretroviral therapy. Incidence of any OI decreased from 15.1 per 100 person-years in the 6 months before therapy to 7.7 in the first 3 months after starting treatment, 2.6 in the following 6 months, and 2.2 per 100 person-years between 9 and 15 months. Reductions in incidence ranged from 38% per month for Kaposi sarcoma (P<.001) to 5% per month for non-Hodgkin lymphoma (P = .31). Baseline CD4 cell count continued to predict the risk of disease progression after initiating potent therapy. Compared with CD4 cell counts above 200 x 10(6)/L, the hazard ratio for developing Ols was 2.5 (95% confidence interval [CI], 1.4-4.5) for counts between 51 and 200 x 10(6)/L and 5.8 (95% CI, 3.2-10.5) for counts below 51 x 10(6)/L at baseline. Independent of baseline CD4 cell count, a rise in CD4 cell count by 50 x 10(6)/L or more and undetectable HIV-1 RNA in plasma (<400 copies/mL) by 6 months reduced risk of subsequent events, with hazard ratios of 0.32 (95% CI, 0.20-0.52) and 0.39 (0.24-0.65), respectively. CONCLUSIONS: Our data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy. Baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy. Individuals with CD4 cell counts of 50 x 10(6)/L or below may need close clinical surveillance after initiation of potent therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., & Leibowitch, J. (1997) · Science · doi:10.1126/science.277.5322.112 · Cited by 1,785
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., et al. (1998) · JAMA · doi:10.1001/jama.280.1.78 · Cited by 995
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Self-citationEgger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Self-citationLi, T., Tubiana, R., Katlama, C., Calvez, V, Mohand, H. A., & Autran, B. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10291-4 · Cited by 544
Race, E. M., Adelson-Mitty, J., Kriegel, G. R., Barlam, T. F., Reimann, K. A., Letvin, N. L., & Japour, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04352-3 · Cited by 358
Ledergerber, B., Telenti, A., & Egger, M. (1999) · BMJ · doi:10.1136/bmj.319.7201.23 · Cited by 247
Self-citationWeverling, G. J., Mocroft, A., Ledergerber, B., Kirk, O., Gonzales-Lahoz, J., Monforte, A. D., Proenca, R., Phillips, A. N., Lundgren, J. D., & Reiss, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03287-0 · Cited by 220
Self-citationImmune Recovery Vitritis Associated With Inactive Cytomegalovirus Retinitis: A New Syndrome
Karavellas, M. P., Lowder, C. Y., Macdonald, J. C., Avila, C. P., & Freeman, W. R. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.2.169 · Cited by 212
HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice
Perrin, L., & Telenti, A. (1998) · Science · doi:10.1126/science.280.5371.1871 · Cited by 193
Self-citationEffect of HAART on natural history of AIDS-related opportunistic disorders
Sepkowitz, K. A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78279-9 · Cited by 184
Opportunistic infections occurring during highly active antiretroviral treatment
Michelet, C., Arvieux, C., François, C., Besnier, J. M., Rogez, J. P., Breux, J. P., Souala, F., Allavena, C., Raffi, F., Garre, M., et al. (1998) · AIDS · doi:10.1097/00002030-199814000-00013 · Cited by 179
Miller, V., Mocroft, A., Reiss, P., Katlama, C., Papadopoulos, A. I., Katzenstein, T., van Lunzen, J., Antunes, F., Phillips, A. N., Lundgren, J. D., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00005 · Cited by 169
High Incidence of Herpes Zoster in Patients with AIDS Soon After Therapy with Protease Inhibitors
Martínez, E., Gatell, J. M., Moran, Y., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/515019 · Cited by 143
Urrer, H. A. F., Gger, M. A. E., Pravil, M. I. O., Ernasconi, E. N. B., Irschel, B. E. H., Attegay, M. A. B., Elenti, A. M. T., Ietro, P., Ernazza, L. V., Ickenbach, M. A. R., et al. (1999) · Cited by 124
Saquinavir Soft-Gel Capsule Formulation
Perry, C. M., & Noble, S. (1998) · Drugs · doi:10.2165/00003495-199855030-00014 · Cited by 119
Crump, J. A., Tyrer, M., Lloyd‐Owen, S. J., Han, L. Y., Lipman, M. C. I., & Johnson, M. A. (1998) · Clinical Infectious Diseases · doi:10.1086/517636 · Cited by 113
HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia.
Hengge, U. R., Goos, M., Esser, S., Exner, V., Dötterer, H., Wiehler, H., Borchard, C., Müller, K. M., Beckmann, A., Eppner, M.-T., et al. (1998) · PubMed · Cited by 101
Chêne, G., Binquet, C., Moreau, J., Neau, D., Pellegrin, I., Malvy, D. J.-M., Ceccaldi, J., Lacoste, D., & Dabis, F. (1998) · AIDS · doi:10.1097/00002030-199817000-00013 · Cited by 74
Progress and Problems in the Fight against AIDS
Hirschel, B. J., & Francioli, P. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381310 · Cited by 67
Self-citation
Cited by
Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.-C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03232-3 · Cited by 894
Self-citationClavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Trends in cancer risk among people with AIDS in the United States 1980–2002
Engels, E. A., Pfeiffer, R. M., Goedert, J. J., Virgo, P., McNeel, T. S., Scoppa, S. M., & Biggar, R. J. (2006) · AIDS · doi:10.1097/01.aids.0000238411.75324.59 · Cited by 775
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Badri, M., Wilson, D., & Wood, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08904-3 · Cited by 556
Metadata
- Authors
- Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., Kaufmann, D., Sudre, P., Francioli, P., Telenti, A., & Study, F. T. S. H. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-12-15
- Volume
- 282
- Issue
- 23
- Pages
- 2220
- ISSN
- 0098-7484
- OpenAlex
- W2137611357
- Cited by
- 481
- References
- 23
- FWCI
- 27.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.